MedTrace Logo

Safety, Efficacy and PK/PD of POL7080 in Patients With Exacerbation of Non-cystic Fibrosis Bronchiectasis.

NCT02096315 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-02-01

No results posted yet for this study

Summary

To test whether POL7080 is effective in patients with exacerbation of non-cystic fibrosis bronchiectasis caused by Pseudomonas aeruginosa infection.

Conditions

Interventions

DRUG

POL7080

Intravenous infusion

Sponsors & Collaborators

  • Polyphor Ltd.

    lead INDUSTRY

Principal Investigators

  • Eva Polverino, MD · Hospital Clinic, Barcelona, SPAIN

  • Adam Hill, MD PhD · Royal Infirmary, Edinburgh, U.K.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-11-30
Completion
2015-11-30

Countries

  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02096315 on ClinicalTrials.gov